Trial Profile

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capivasertib (Primary) ; Docetaxel (Primary) ; Prednisolone; Prednisone
Indications Adenocarcinoma; Prostate cancer
Focus Registrational; Therapeutic Use
Acronyms CAPItello-280
Sponsors AstraZeneca

29 Apr 2025 Status changed from active, no longer recruiting to discontinued based on the recommendation of the Independent Data Monitoring Committee (IDMC) following their review of data from a pre-specified interim analysis.
27 Jan 2025 Planned End Date changed from 21 Dec 2026 to 4 Mar 2026.
27 Jan 2025 Planned primary completion date changed from 21 Dec 2026 to 4 Mar 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com